SCHEMBL21664090

SCHEMBL21664090

c1ccc2ncc(C3=NCCS3)cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.53
PDGFRA P16234 4/20 0.53
NISCH Q9Y2I1 1/20 0.52
CYP2A6 P11509 1/20 0.46
BIRC5 O15392 1/20 0.45
PIK3CD O00329 2/20 0.44
PIK3CA P42336 2/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CYP1A2 P05177 1/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAP4K4 O95819 1/20 0.40
CSNK1G2 P78368 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
MAP4K5 Q9Y4K4 1/20 0.40
TOP2A P11388 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21663992 0.80 NPC1 (0.59) NISCHPIK3CDPIK3CACYP1A2LMNA
SCHEMBL28434848 0.77 SMN1; SMN2 (0.49) NISCHCYP1A2LMNASMN1; SMN2
SCHEMBL2772360 0.75 PDGFRB (0.77) PDGFRBPDGFRANISCHCYP2A6BIRC5
SCHEMBL32667946 0.75 PDGFRB (0.77) PDGFRBPDGFRANISCHCYP2A6BIRC5
SCHEMBL1147751 0.72 LMNA (0.53) LMNASMN1; SMN2
SCHEMBL27523215 0.71 PDGFRB (0.59) PDGFRBPDGFRANISCHCYP2A6BIRC5
SCHEMBL708999 0.70 PDGFRB (0.75) PDGFRBPDGFRANISCHCYP2A6BIRC5
SCHEMBL2346887 0.69 PDGFRB (1.00) PDGFRBPDGFRANISCHCYP2A6BIRC5
SCHEMBL27631124 0.69 PDGFRB (0.58) PDGFRBPDGFRANISCHCYP2A6BIRC5
SCHEMBL21664135 0.69 KDM4E (0.49) NISCHCA12CA9CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 PDGFRB 3694/4885PDGFRA 3802/4885NISCH 1116/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 PDGFRB 3694/4885PDGFRA 3802/4885NISCH 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.